Journal article
11β-hydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice
AE Coutinho, M Gray, DG Brownstein, DM Salter, DA Sawatzky, S Clay, JS Gilmour, JR Seckl, JS Savill, KE Chapman
Endocrinology | ENDOCRINE SOC | Published : 2012
DOI: 10.1210/en.2011-1398
Open access
Abstract
Glucocorticoids profoundly influence immune responses, and synthetic glucocorticoids are widely used clinically for their potent antiinflammatory effects. Endogenous glucocorticoid action is modulated by the two isozymes of 11β-hydroxysteroid dehydrogenase (11β-HSD). In vivo, 11β-HSD1 catalyzes the reduction of inactive cortisone or 11-dehydrocorticosterone into active cortisol or corticosterone, respectively, thereby increasing intracellular glucocorticoid levels. 11β-HSD2 catalyzes the reverse reaction, inactivating intracellular glucocorticoids. Both enzymes have been postulated to modulate inflammatory responses. In the K/BxN serum transfer model of arthritis, 11β-HSD1-deficient mice sho..
View full abstractGrants
Awarded by UK Research and Innovation
Funding Acknowledgements
This work was supported by Medical Research Council Project Grant G0800235 (to K. E. C., M. G., J.S.S., and J.R.S.) and Wellcome Trust Program Grants WT083184 (to J.R.S. and K. E. C.) and WT064497 (to J.S.S.). M. G. is supported by an Arthritis Research Campaign Clinician Scientist Fellowship.